MorphoSys Market Outperform Rating Reiterated at JMP Securities
Slightly above 67% of MorphoSys' investor base is looking to short. The analysis of current outlook of investing in MorphoSys AG ADR suggests that many traders are alarmed regarding MorphoSys' prospects. MorphoSys' investing sentiment overview a quick insight into current market opportunities from investing in MorphoSys AG ADR. Many technical investors use MorphoSys AG ADR stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
MorphoSys |
JMP Securities reiterated their market outperform rating on shares of MorphoSys in a report issued on Tuesday, Benzinga reports. The brokerage currently has a 17.00 price target on the stock. A number of other brokerages have also commented on MOR. The Goldman Sachs Group raised MorphoSys from a sell rating to
Read at thelincolnianonline.com
MorphoSys Fundamental Analysis
We analyze MorphoSys' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of MorphoSys using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of MorphoSys based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Cash Per Share
Cash Per Share Comparative Analysis
MorphoSys is currently under evaluation in cash per share category among its peers. Cash per Share is a ratio of current cash on hands or in the banks of the company to a total number of shares outstanding. It is used to determine a firm's liquidity and is a good indicator of the overall financial health of a company. Value investors often compare this ratio to the current stock quote, and if it exceeds the stock price they would invest in it.
MorphoSys AG ADR Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with MorphoSys stock to make a market-neutral strategy. Peer analysis of MorphoSys could also be used in its relative valuation, which is a method of valuing MorphoSys by comparing valuation metrics with similar companies.
Peers
MorphoSys Related Equities
IMRX | Immuneering Corp | 6.88 | ||||
MRSN | Mersana Therapeutics | 5.63 | ||||
LYRA | Lyra Therapeutics | 5.56 | ||||
NVCT | Nuvectis Pharma | 3.98 | ||||
KRON | Kronos Bio | 2.17 | ||||
VTYX | Ventyx Biosciences | 2.15 | ||||
GOSS | Gossamer Bio | 1.19 | ||||
ACLX | Arcellx | 0.08 | ||||
MLYS | Mineralys Therapeutics, | 0.39 | ||||
PMVP | Pmv Pharmaceuticals | 0.66 | ||||
RLYB | Rallybio Corp | 1.09 | ||||
ELVN | Enliven Therapeutics | 1.50 | ||||
GLUE | Monte Rosa | 2.22 | ||||
EWTX | Edgewise Therapeutics | 3.10 | ||||
IMCR | Immunocore Holdings | 3.44 | ||||
GBIO | Generation Bio | 3.60 | ||||
IPSC | Century Therapeutics | 3.70 | ||||
REPL | Replimune | 4.14 | ||||
CCCC | C4 Therapeutics | 5.25 | ||||
PCVX | Vaxcyte | 5.61 | ||||
CGEM | Cullinan Oncology | 6.82 |
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. You can also try the Sync Your Broker module to sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors..
Other Consideration for investing in MorphoSys Stock
If you are still planning to invest in MorphoSys AG ADR check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the MorphoSys' history and understand the potential risks before investing.
Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
Bonds Directory Find actively traded corporate debentures issued by US companies | |
Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. |